NASDAQ$PGEN
Precigen Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Precigen's financial performance for Q2 2020 was announced, featuring a total revenue of $30.4 million and a net loss of $43.4 million.
Precigen reported a second-quarter revenue of $30.4 million and a net loss of $43.4 million, or $(0.26) per basic share. The company highlighted progress in clinical trials and the development of its UltraPorator manufacturing device.
- Advanced the development of UltraPorator™ electroporation device, initiating cGMP manufacturing and technology transfer.
- Initiated patient dosing in the third dose level of the Phase 1 clinical trial of PRGN-3005 UltraCAR-T for advanced ovarian cancer.
- AG019 ActoBiotics™ Phase 1b monotherapy study met the primary endpoint for safety and tolerability in patients with early-onset type 1 diabetes.
- INXN-4001 Phase I trial for heart failure met primary endpoints for safety and feasibility, with preliminary data suggesting improved patient outcomes.
Headline financials
Revenue & EPS history
Precigen · Revenue · Quarterly
$30.4M
Revenue by segment
Precigen · $26.1M total across 3 segments · Q2 2020
- Service revenue$17.4M-5.5%66.6%
- Product revenue$8.54M+9.5%32.7%
- Collab & licensing$188K+1.1%0.7%
Forward guidance
Precigen maintained its guidance for clinical readouts in 2020, anticipating additional results from clinical programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2020
+0.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+1.4%
Avg return
30 days after
50%
26 / 52 earnings
Positive
+31.0%
Q2 2023
Best reaction
-38.9%
Q4 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q1 2026 | +1.7% | -0.2% | — | |
| Q3 2025 | +25.6% | +9.3% | -4.4% | |
| Q2 2025 | +6.1% | +63.9% | +110.6% | |
| Q1 2025 | -2.8% | -5.7% | +0.7% | |
| Q4 2024 | +0.6% | -4.5% | -22.3% | |
| Q3 2024 | -10.4% | -13.0% | -26.1% | |
| Q1 2024 | +6.7% | +2.2% | +25.9% | |
| Q4 2023 | +3.6% | +0.7% | -5.0% | |
| Q3 2023 | -13.5% | -19.8% | -6.3% | |
| Q2 2023 | +31.0% | +43.1% | +39.7% | |
| Q1 2023 | -9.5% | -4.0% | -6.3% | |
| Q4 2022 | +16.4% | -6.0% | -15.5% | |
| Q3 2022 | +11.2% | +18.1% | -2.5% | |
| Q2 2022 | +11.6% | +14.5% | +11.1% | |
| Q1 2022 | +3.2% | +8.0% | +23.2% | |
| Q4 2021 | -1.3% | -10.2% | -6.2% | |
| Q3 2021 | -7.1% | -11.8% | -33.3% | |
| Q2 2021 | +8.6% | +10.4% | +10.6% | |
| Q1 2021 | -0.2% | +5.7% | +9.5% | |
| Q4 2020 | +1.7% | +0.1% | -18.4% | |
| Q3 2020 | +22.2% | +20.4% | +69.7% | |
| Q2 2020 | -5.7% | -8.8% | -1.0% | |
| Q1 2020 | -5.9% | -4.2% | -4.7% | |
| Q4 2019 | -14.5% | -19.0% | -27.4% | |
| Q3 2019 | -1.1% | +2.0% | +6.3% | |
| Q2 2019 | -7.2% | -10.3% | -23.4% | |
| Q1 2019 | -1.1% | +0.7% | +22.2% | |
| Q4 2018 | -38.9% | -39.4% | -36.5% | |
| Q3 2018 | -19.3% | -24.4% | -32.1% | |
| Q2 2018 | -5.7% | -4.6% | -2.9% | |
| Q1 2018 | -19.5% | -13.0% | -9.3% | |
| Q4 2017 | +23.6% | +20.9% | +17.7% | |
| Q3 2017 | -25.3% | -19.7% | -15.9% | |
| Q2 2017 | -5.2% | -4.0% | -15.0% | |
| Q1 2017 | +21.5% | +32.0% | +15.0% | |
| Q4 2016 | +5.8% | +2.1% | -11.0% | |
| Q3 2016 | +14.1% | +24.0% | +15.7% | |
| Q2 2016 | +3.3% | +4.5% | +0.9% | |
| Q1 2016 | -5.1% | — | — | |
| Q4 2015 | -0.1% | — | — | |
| Q3 2015 | +9.7% | — | — | |
| Q2 2015 | -17.8% | — | — | |
| Q1 2015 | +3.2% | — | — | |
| Q4 2014 | +17.3% | — | — | |
| Q3 2014 | -3.9% | — | — | |
| Q2 2014 | -2.9% | — | — | |
| Q1 2013 | +2.9% | — | — | |
| Q1 2014 | -11.7% | — | — | |
| Q4 2013 | +5.5% | — | — | |
| Q3 2012 | +3.6% | — | — | |
| Q3 2013 | +3.6% | — | — | |
| Q2 2013 | -7.8% | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro